Polyphoshoinositide binding peptides for intracellular drug delivery

• US 5,846,743 A
• Filed: 11/22/1996
• Issued: 12/08/1998
• Est. Priority Date: 02/22/1995
• Status: Expired due to Fees

• Current Assignee: Brigham and Women's Hospital Incorporated
• Original Assignee: Brigham and Women's Hospital Incorporated
• Inventors: Cunningham, C. Casey, Hartwig, John H., Janmey, Paul A., Stossel, Thomas P., Vegner, Roland
• Primary Examiner(s): Prouty, Rebecca E.
• Assistant Examiner(s): Longton, Enrique D.
• Application Number:
  US08/755,496
• Time in Patent Office: 746 Days
• Field of Search: 514/15, 514/16, 530/328, 435/244, 435/4, 435/6, 435/7.21, 435/7.23, 435/7.8
• US Class Current: 435/7.8
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/4702 Regulators; Modulating activity
• CPC Class Codes: C07K 14/4735 Villin
• CPC Class Codes: C07K 7/06 having 5 to 11 amino acids

Abstract

Methods and compositions for facilitating the transport of a membrane-impermeable extracellular agent having an intracellular activity across the membrane of a cell are provided. The methods involve covalently coupling an amino terminal blocking group to a transport-mediating peptide to form a carrier molecule. The carrier molecule is covalently coupled to the extracellular agent to form a membrane-permeable prodrug. The transport-mediating peptides are highly basic and bind to polyphosphoinositides.

Claims

1. A compound comprising:

(i) a carrier molecule for facilitating the transport of a membrane-impermeable extracellular agent having an intracellular activity across a membrane of a cell, the carrier molecule having the formula;

space="preserve" listing-type="equation">X-P,

wherein

P is a transport-mediating peptide selected from the group consisting of Seq. I.D. Nos. 1-35 and 36; and

X is a terminal amine derivatizing agent that is covalently coupled to the N-terminus amine of the transport-mediating peptide,

wherein each of the functionally equivalent peptides is a basic polyphosphoinositide binding peptide containing between three and ten amino acids, and

(ii) a membrane-impermeable extracellular agent, A, covalently coupled to the carboxyl terminus of the transport-mediating peptide to form a prodrug having the formula, X-P-A.

2. The carrier molecule of claim 1, wherein the extracellular agent is selected from the group consisting of a peptide, an oligonucleotide, an antibiotic, an antimicotic, an anti-viral agent, an anti-cancer agent, an enzyme, an enzyme modulator, and an imaging agent.

3. The carrier molecule of claim 2, wherein the extracellular agent is selected from the group consisting of a peptide, an oligonucleotide and an antibiotic.

4. The carrier molecule of claim 1, further comprising a pharmaceutically acceptable carrier.

5. An isolated cell containing the composition of claim 1.

6. The cell of claim 5, wherein the cell is selected from the group consisting of a melanoma cell, a fibroblast, a neuronal cell, a platelet, a monocyte and a neutrophil.

7. The cell of claim 5, wherein the cell is a fixed cell.

8. A method for facilitating transport of a membrane-impermeable extracellular agent having an intracellular activity across the membrane of a cell, the method comprising:

contacting the cell with the compound of claim 1 for a time sufficient to permit transport of the compound of claim 1 across the cell membrane.

9. The method of claim 8, wherein transport of the extracellular agent across the cell membrane is completed in between about 10 and about 300 seconds.

10. The method of claim 8, wherein the derivatizing agent is a fluorescent molecule that is covalently coupled to the N-terminal amine of the transport-mediating peptide.

11. The method of claim 10, wherein the fluorescent molecule is selected from the group consisting of rhodamine, a rhodamine derivative, fluorescein, a fluorescein derivative, biotin, and a biotin derivative.

12. The method of claim 11, wherein the fluorescent molecule is rhodamine and wherein the transport-mediating peptide is selected from the group consisting of Sequence I.D. Nos. 1 and 2.

13. The method of claim 8, wherein the membrane-impermeable extracellular agent is selected from the group consisting of a peptide, an oligonucleotide, an antibiotic, an antimicotic, an anti-viral agent, an anti-cancer agent, an enzyme, an enzyme modulator and an imaging agent.

14. The method of claim 8, wherein the step of contacting the cell with the compound is performed in vitro.

15. The method of claim 8, wherein the step of contacting the cell with the compound comprises adding the prodrug to a cell culture.

16. The method of claim 15, wherein the membrane-impermeable extracellular agent is an antibiotic.

17. The method of claim 14, wherein the membrane-impermeable extracellular agent is an oligonucleotide, further comprising the steps of allowing the oligonucleotide to hybridize to an intracellular target nucleic acid and detecting the target nucleic acid.

18. The method of claim 17, wherein the cell is a fixed cell.

19. The method of claim 8, wherein the step of contacting the cell with the compound is performed in vivo.

20. The method of claim 19, wherein the membrane-impermeable extracellular agent is an imaging agent.

21. A compound comprising:

(i) a carrier molecule for facilitating the transport of a membrane-impermeable extracellular agent having an intracellular activity across a membrane of a cell, the carrier molecule having the formula;

space="preserve" listing-type="equation">X-P,

wherein

P is a transport-mediating peptide that is a peptide fragment of a peptide selected from the group consisting of Seq. I.D. No. 1 and Seq. I.D. No.2, wherein the peptide fragment is a basic polyphosphoinositide binding peptide and contains between three and ten amino acids, and X is a terminal amine derivatizing agent that is covalently coupled to the N-terminus amine of the transport-mediating peptide,

(ii) a membrane-impermeable extracellular agent, A, covalently coupled to the carboxyl terminus of the transport-mediating peptide to form a compound having the formula, X-P-A.

22. The carrier molecule of claim 21, wherein the extracellular agent is selected from the group consisting of a peptide, an oligonucleotide, an antibiotic, an antimicotic, an anti-viral agent, an anti-cancer agent, an enzyme, an enzyme modulator, and an imaging agent.

23. The carrier molecule of claim 22, wherein the extracellular agent is selected from the group consisting of a peptide, an oligonucleotide and an antibiotic.

24. The carrier molecule of claim 21, further comprising a pharmaceutically acceptable carrier.

25. An isolated cell containing the composition of claim 21.

26. The cell of claim 25, wherein the cell is selected from the group consisting of a melanoma cell, a fibroblast, a neuronal cell, a platelet, a monocyte and a neutrophil.

27. The cell of claim 25, wherein the cell is a fixed cell.

28. A method for facilitating transport of a membrane-impermeable extracellular agent having an intracellular activity across the membrane of a cell, the method comprising:

contacting the cell with the compound of claim 21 for a time sufficient to permit transport of the compound of claim 21 across the cell membrane.

29. The method of claim 28, wherein transport of the extracellular agent across the cell membrane is completed in between about 10 and about 300 seconds.

30. The method of claim 28, wherein the derivatizing agent is a fluorescent molecule that is covalently coupled to the N-terminal amine of the transport-mediating peptide.

31. The method of claim 30, wherein the fluorescent molecule is selected from the group consisting of rhodamine, a rhodamine derivative, fluorescein, a fluorescein derivative, biotin, and a biotin derivative.

32. The method of claim 31, wherein the fluorescent molecule is rhodamine.

33. The method of claim 28, wherein the membrane-impermeable extracellular agent is selected from the group consisting of a peptide, an oligonucleotide, an antibiotic, an antimicotic, an anti-viral agent, an anti-cancer agent, an enzyme, an enzyme modulator and an imaging agent.

34. The method of claim 28, wherein the step of contacting the cell with the compound is performed in vitro.

35. The method of claim 28, wherein the step of contacting the cell with the compound comprises adding the compound to a cell culture.

36. The method of claim 35, wherein the membrane-impermeable extracellular agent is an antibiotic.

37. The method of claim 34, wherein the membrane-impermeable extracellular agent is an oligonucleotide, further comprising the steps of allowing the oligonucleotide to hybridize to an intracellular target nucleic acid and detecting the target nucleic acid.

38. The method of claim 37, wherein the cell is a fixed cell.

39. The method of claim 28, wherein the step of contacting the cell with the compound is performed in vivo.

40. The method of claim 39, wherein the membrane-impermeable extracellular agent is an imaging agent.

41. A compound comprising:

(i) a carrier molecule for facilitating the transport of a membrane-impermeable extracellular agent having an intracellular activity across a membrane of a cell, the carrier molecule having the formula;

space="preserve" listing-type="equation">X-P,

wherein

P is a transport-mediating peptide that is a polyphosphoinositide binding peptide comprising between three and ten amino acids of a polyphosphoinositide domain of a polyphosphoinositide binding protein, wherein the polyphosphoinositide domain comprises a sequence selected from the group consisting of (K/R)xxx(K/R)x(K/R)(K/R) and (K/R)xxxx(K/R)x(K/R)(K/R), SEQ. ID. NO. 37 and SEQ. ID. NO;

38, respectively wherein (K/R) represents lysine or arginine and x represents a neutral amino acid; and

X is a terminal amine derivatizing agent that is covalently coupled to the N-terminus amine of the transport-mediating peptide,

(ii) a membrane-impermeable extracellular agent, A, covalently coupled to the carboxyl terminus of the transport-mediating peptide to form a compound having the formula, X-P-A.

42. The carrier molecule of claim 41, wherein the extracellular agent is selected from the group consisting of a peptide, an oligonucleotide, an antibiotic, an antimicotic, an anti-viral agent, an anti-cancer agent, an enzyme, an enzyme modulator, and an imaging agent.

43. The carrier molecule of claim 42, wherein the extracellular agent is selected from the group consisting of a peptide, an oligonucleotide and an antibiotic.

44. The carrier molecule of claim 41, further comprising a pharmaceutically acceptable carrier.

45. An isolated cell containing the composition of claim 41.

46. The cell of claim 45, wherein the cell is selected from the group consisting of a melanoma cell, a fibroblast, a neuronal cell, a platelet, a monocyte and a neutrophil.

47. The cell of claim 45, wherein the cell is a fixed cell.

48. A method for facilitating transport of a membrane-impermeable extracellular agent having an intracellular activity across the membrane of a cell, the method comprising:

contacting the cell with the compound of claim 41 for a time sufficient to permit transport of the compound of claim 41 across the cell membrane.

49. The method of claim 48, wherein transport of the extracellular agent across the cell membrane is completed in between about 10 and about 300 seconds.

50. The method of claim 48, wherein the derivatizing agent is a fluorescent molecule that is covalently coupled to the N-terminal amine of the transport-mediating peptide.

51. The method of claim 50, wherein the fluorescent molecule is selected from the group consisting of rhodamine, a rhodamine derivative, fluorescein, a fluorescein derivative, biotin, and a biotin derivative.

52. The method of claim 51, wherein the fluorescent molecule is rhodamine.

53. The method of claim 48, wherein the membrane-impermeable extracellular agent is selected from the group consisting of a peptide, an oligonucleotide, an antibiotic, an antimicotic, an anti-viral agent, an anti-cancer agent, an enzyme, an enzyme modulator and an imaging agent.

54. The method of claim 48, wherein the step of contacting the cell with the compound is performed in vitro.

55. The method of claim 48, wherein the step of contacting the cell with the compound comprises adding the compound to a cell culture.

56. The method of claim 55, wherein the membrane-impermeable extracellular agent is an antibiotic.

57. The method of claim 54, wherein the membrane-impermeable extracellular agent is an oligonucleotide, further comprising the steps of allowing the oligonucleotide to hybridize to an intracellular target nucleic acid and detecting the target nucleic acid.

58. The method of claim 57, wherein the cell is a fixed cell.

59. The method of claim 48, wherein the step of contacting the cell with the compound is performed in vivo.

60. The method of claim 59, wherein the membrane-impermeable extracellular agent is an imaging agent.